Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122822 | 1.00 | ACACB (0.33) | ACACBMMEITGA4ITGB7ALDH1A1 | |
| SCHEMBL888696 | 1.00 | ACACB (0.33) | ACACBMMEITGA4ITGB7ALDH1A1 | |
| SCHEMBL14864778 | 0.86 | MME (0.32) | ACACBMMEITGA4ITGB7ALDH1A1 | |
| SCHEMBL14850463 | 0.86 | MME (0.32) | ACACBMMEITGA4ITGB7ALDH1A1 | |
| SCHEMBL14886286 | 0.84 | MME (0.31) | ACACBMMEITGA4ITGB7 | |
| SCHEMBL10120407 | 0.83 | MME (0.31) | ACACBMMEITGA4ITGB7 | |
| SCHEMBL888751 | 0.78 | ITGB2 (0.47) | ALDH1A1 | |
| SCHEMBL10122812 | 0.78 | ITGB2 (0.47) | ALDH1A1 | |
| SCHEMBL4788962 | 0.71 | NPC1 (0.37) | ACACB | |
| SCHEMBL10122809 | 0.70 | ACACB (0.46) | ACACBITGA4ITGB7ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ACACB 345/4885MME 2199/4885ITGA4 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.